{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:47:24Z","timestamp":1790668044150,"version":"4.1.0"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.parkreldis.2020.05.026","type":"journal-article","created":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T11:31:58Z","timestamp":1590406318000},"page":"55-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["Treatment of psychosis in Parkinson's disease and dementia with Lewy Bodies: A review"],"prefix":"10.1016","volume":"75","author":[{"given":"Kevin","family":"Kyle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff M.","family":"Bronstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2020.05.026_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2017.07.013","article-title":"Dementia with lewy bodies and Parkinson disease dementia: it is the same disease!","author":"Friedman","year":"2018","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib2","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/mds.26796","article-title":"Abolishing the 1-year rule: how much evidence will be enough?","volume":"31","author":"Postuma","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib3","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.v66n0514","article-title":"Neuroleptic sensitivity in Parkinson's disease and Parkinsonian dementias","author":"Aarsland","year":"2005","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib4","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/jnnp.74.6.720","article-title":"Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older","volume":"74","author":"Rahkonen","year":"2003","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib5","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1055\/s-0034-1381741","article-title":"Dementia with lewy bodies","volume":"34","author":"Mayo","year":"2014","journal-title":"Semin. Neurol."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/bmj.305.6855.673","article-title":"Neuroleptic sensitivity in patients with senile dementia of Lewy body type","volume":"305","author":"McKeith","year":"1992","journal-title":"BMJ"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib7","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib8","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1177\/1756285616664300","article-title":"Evidence for the use of pimavanserin in the treatment of Parkinson's disease psychosis","volume":"9","author":"Sarva","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib9","series-title":"Park. Dis. Mov. Disord","first-page":"51","article-title":"Etiology and pathogenesis of Parkinson's disease","author":"Przedborski","year":"2015"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib10","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/archneur.63.5.713","article-title":"The malignant course of \u201cBenign hallucinations\u201d in Parkinson disease","volume":"63","author":"Goetz","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib11","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/S1353-8020(09)70846-6","article-title":"Hallucinations and psychosis in Parkinson's disease","volume":"15","author":"Rabey","year":"2009","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib12","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/mds.21382","article-title":"Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group","volume":"22","author":"Ravina","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib13","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.43.11.2227","article-title":"Risk factors for nursing home placement in advanced Parkinson's disease","volume":"43","author":"Goetz","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.parkreldis.2005.06.011","article-title":"Caregiver-burden in Parkinson's disease is closely associated with psychiatric symptoms, falls, and disability","volume":"12","author":"Schrag","year":"2006","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/WAD.0b013e3181c72b5d","article-title":"Lewy body dementia","volume":"24","author":"Galvin","year":"2010","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40120-018-0104-1","article-title":"A review of dementia with lewy bodies' impact, diagnostic criteria and treatment","volume":"7","author":"Capouch","year":"2018","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/alzrt251","article-title":"Lewy body dementia: the impact on patients and caregivers","volume":"6","author":"Zweig","year":"2014","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib18","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/brain\/awf033","article-title":"Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe","volume":"125","author":"Harding","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib19","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1093\/brain\/awf251","article-title":"Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease","volume":"125","author":"Harding","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib20","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1093\/brain\/awr225","article-title":"Testing an aetiological model of visual hallucinations in Parkinson's disease","volume":"134","author":"Gallagher","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib21","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.parkreldis.2005.10.005","article-title":"Cortical and amygdalar Lewy body burden in Parkinson's disease patients with visual hallucinations","volume":"12","author":"Papapetropoulos","year":"2006","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib22","article-title":"Levodopa-induced psychosis: a kindling phenomenon","author":"Moskovitz","year":"1978","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib23","doi-asserted-by":"crossref","DOI":"10.1007\/BF01663632","article-title":"Responsibility of extrastriatal areas for the appearance of psychotic symptoms (Clinical and biochemical human post-mortem findings)","author":"Birkmayer","year":"1975","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib24","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.2174\/138920112800784880","article-title":"Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia","volume":"13","author":"Meltzer","year":"2012","journal-title":"Curr. Pharmaceut. Biotechnol."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib25","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-011-6149-z","article-title":"The pedunculopontine nucleus is related to visual hallucinations in Parkinson's disease: preliminary results of a voxel-based morphometry study","author":"Janzen","year":"2012","journal-title":"J. Neurol."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib26","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1136\/jnnp-2012-303391","article-title":"Neuroanatomical substrates of visual hallucinations in patients with non-demented Parkinson's disease","volume":"83","author":"Shin","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/13543784.2016.1121995","article-title":"Potential serotonergic agents for the treatment of schizophrenia","volume":"25","author":"Garay","year":"2016","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib28","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.2174\/1570159X15666170413115754","article-title":"Aripiprazole, A drug that displays partial agonism and functional selectivity","volume":"15","author":"Tuplin","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib29","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/BF00380972","article-title":"Treatment of drug-induced exogenous psychosis in Parkinsonism with clozapine and fluperlapine","volume":"235","author":"Scholz","year":"1985","journal-title":"Eur. Arch. Psychiatry Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib30","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/14656566.2018.1445721","article-title":"Pharmacological interventions for psychosis in Parkinson's disease patients","volume":"19","author":"Friedman","year":"2018","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib31","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1212\/WNL.40.5.832","article-title":"Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis","volume":"40","author":"Wolters","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib32","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","article-title":"Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease","volume":"340","author":"Parkinson Study Group","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib33","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","article-title":"Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up","volume":"75","author":"Pollak","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib34","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1212\/WNL.49.6.1587","article-title":"Clozapine in Parkinson's disease tremor: effects of acute and chronic administration","volume":"49","author":"Bonuccelli","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib35","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1600-0404.1994.tb01677.x","article-title":"Clozapine in the treatment of tremor in Parkinson's disease","volume":"89","author":"Jansen","year":"2009","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib36","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1212\/WNL.48.4.1077","article-title":"Benztropine versus clozapine for the treatment of tremor in Parkinson's disease","volume":"48","author":"Friedman","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib37","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1176\/jnp.5.2.206","article-title":"Clozapine use in diffuse Lewy body disease","volume":"5","author":"Chacko","year":"1993","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib38","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000106630","article-title":"Drug treatment in Lewy body dementia","volume":"8","author":"Geroldi","year":"1997","journal-title":"Dement. Geriatr. Cognit. Disord."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-224710","article-title":"Successful management of persistent distressing neuropsychiatric symptoms by clozapine in a patient suffering from dementia with Lewy bodies","volume":"2018","author":"Bhamra","year":"2018","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib40","first-page":"287","article-title":"The use of clozapine and levodopa for the treatment of persistent visual hallucinations and parkinsonism in Lewy body dementia","volume":"55","author":"Archie","year":"2013","journal-title":"Tijdschr Psychiatr."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib41","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1176\/jnp.10.2.227","article-title":"Neuroleptic sensitivity to clozapine in dementia with lewy bodies","volume":"10","author":"Burke","year":"1998","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib42","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.wnf.0000136891.17006.ec","article-title":"Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis","volume":"27","author":"Morgante","year":"2004","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib43","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1212\/01.WNL.0000110317.52453.6C","article-title":"Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study","volume":"62","author":"Durif","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib44","doi-asserted-by":"crossref","DOI":"10.1111\/j.1600-0404.1998.tb05955.x","article-title":"Low dosage clozapine effects on L-dopa induced dyskinesias in parkinsonian patients","author":"Pierelli","year":"1998","journal-title":"Acta Neurol. Scand."},{"issue":"Suppl 3","key":"10.1016\/j.parkreldis.2020.05.026_bib45","first-page":"3","article-title":"Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry","volume":"59","author":"Honigfeld","year":"1998","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib46","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.parkreldis.2015.12.009","article-title":"Multiple re-challenges for clozapine neutropenia in Parkinson's disease","volume":"23","author":"Komaragiri","year":"2016","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib48","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/mds.27378","article-title":"Quetiapine for Parkinson's Disease psychosis: evidence-based medicine versus expert belief: a case study","volume":"33","author":"Friedman","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib49","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00415-005-0943-4","article-title":"The effect of quetiapine in psychotic Parkinsonian patients with and without dementia","volume":"253","author":"Prohorov","year":"2006","journal-title":"J. Neurol."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib50","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/1531-8257(199905)14:3<484::AID-MDS1016>3.0.CO;2-B","article-title":"Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease","volume":"14","author":"Fernandez","year":"1999","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib51","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/mds.10620","article-title":"Quetiapine improves psychotic symptoms and cognition in Parkinson's disease","volume":"19","author":"Juncos","year":"2004","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib52","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/mds.10176","article-title":"The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia","volume":"17","author":"Reddy","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib53","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.10374","article-title":"Long-term outcome of quetiapine use for psychosis among parkinsonian patients","volume":"18","author":"Fernandez","year":"2003","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib54","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/mds.20474","article-title":"Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease","volume":"20","author":"Ondo","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib55","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.21116","article-title":"Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration","volume":"22","author":"Rabey","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib56","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/NDT.S5335","article-title":"A randomized controlled trial of quetiapine for psychosis in Parkinson\u2019s disease","volume":"5","author":"Shotbolt","year":"2009","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib57","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.3109\/00207450903222758","article-title":"Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study","volume":"119","author":"Fernandez","year":"2009","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib58","doi-asserted-by":"crossref","first-page":"s89","DOI":"10.1007\/s100720200084","article-title":"Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease","volume":"23","author":"Morgante","year":"2002","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib59","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/01.WNF.0000236769.31279.19","article-title":"Rater-blinded, prospective comparison","volume":"29","author":"Merims","year":"2006","journal-title":"Clin. Neuropharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.parkreldis.2020.05.026_bib60","first-page":"16","article-title":"Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms","volume":"65","author":"Baskys","year":"2004","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib61","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0278-5846(03)00040-X","article-title":"Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy bodies: a case series","volume":"27","author":"Takahashi","year":"2003","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib62","doi-asserted-by":"crossref","first-page":"513","DOI":"10.4088\/JCP.v63n0608","article-title":"Quetiapine for psychosis in Parkinson's disease versus dementia with lewy bodies","volume":"63","author":"Fernandez","year":"2002","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib63","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1212\/01.wnl.0000260060.60870.89","article-title":"Quetiapine for agitation or psychosis in patients with dementia and parkinsonism","volume":"68","author":"Kurlan","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib64","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1177\/1533317506294775","article-title":"Efficacy and tolerability of quetiapine in the treatment of behavioral and psychological symptoms of dementia","volume":"21","author":"Onor","year":"2007","journal-title":"Am. J. Alzheimer's Dis. Other Dementias"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib65","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/npp.2009.176","article-title":"Pimavanserin, a Serotonin2A receptor inverse agonist, for the treatment of Parkinson's disease psychosis","volume":"35","author":"Meltzer","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib66","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib67","doi-asserted-by":"crossref","first-page":"898.e1","DOI":"10.1016\/j.jamda.2015.06.021","article-title":"Impact of current antipsychotic medications on comparative mortality and adverse events in people with Parkinson disease psychosis","volume":"16","author":"Ballard","year":"2015","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib68","doi-asserted-by":"crossref","DOI":"10.1017\/S1092852918000202","article-title":"Use of pimavanserin in patients with Parkinson's disease psychosis: subgroup Analysis of efficacy and safety in patients with and without cognitive impairment","volume":"23","author":"Weintraub","year":"2018","journal-title":"CNS Spectr."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib69","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3233\/JAD-150818","article-title":"Serotonin 2A receptor inverse agonist as a treatment for Parkinson's disease psychosis: a systematic review and meta-analysis of serotonin 2A receptor negative modulators","volume":"50","author":"Yasue","year":"2016","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib71","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/WNF.0000000000000219","article-title":"A retrospective study of pimavanserin use in a movement disorders clinic","volume":"40","author":"Friedman","year":"2017","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib72","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/WNF.0000000000000296","article-title":"Pimavanserin for psychotic symptoms in people with parkinsonism","volume":"41","author":"Friedman","year":"2018","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib74","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/S0140-6736(18)31002-X","article-title":"Pimavanserin evaluated by the FDA","volume":"391","author":"Webster","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib76","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1212\/WNL.0000000000006396","article-title":"Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine","volume":"91","author":"Moreno","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib77","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1212\/WNL.47.4.1085","article-title":"Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease","volume":"47","author":"Wolters","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib78","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/mds.10217","article-title":"Olanzapine treatment for dopaminergic-induced hallucinations","volume":"17","author":"Ondo","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib79","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0006-3223(02)01392-6","article-title":"Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease","volume":"52","author":"Breier","year":"2002","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib80","doi-asserted-by":"crossref","first-page":"150","DOI":"10.12688\/f1000research.2-150.v1","article-title":"A fixed-dose randomized controlled trial of olanzapine for psychosis in Parkinson disease","volume":"2","author":"Nichols","year":"2013","journal-title":"F1000Research"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib81","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1212\/WNL.55.6.789","article-title":"Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients","volume":"55","author":"Goetz","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib82","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/(SICI)1099-1166(199906)14:6<459::AID-GPS957>3.0.CO;2-R","article-title":"Olanzapine in dementia with Lewy bodies: a clinical study","volume":"14","author":"Walker","year":"1999","journal-title":"Int. J. Geriatr. Psychiatr."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib83","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000048636","article-title":"Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies","volume":"13","author":"Cummings","year":"2002","journal-title":"Dement. Geriatr. Cognit. Disord."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib84","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/00002826-200401000-00003","article-title":"Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience","volume":"27","author":"Fernandez","year":"2004","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib85","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1176\/jnp.12.3.364","article-title":"Clozapine and risperidone treatment of psychosis in Parkinson's disease","volume":"12","author":"Ellis","year":"2000","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib86","first-page":"556","article-title":"Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes","volume":"56","author":"Rich","year":"1995","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib87","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(94)92114-8","article-title":"Risperidone in Parkinson's disease","volume":"344","author":"Ford","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib88","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S0140-6736(94)92511-9","article-title":"Risperidone for hallucinations in levodopa-treated Parkinson's disease patients","volume":"343","author":"Meco","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib89","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/S0140-6736(05)78999-6","article-title":"Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease","volume":"351","author":"Ballard","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib90","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0140-6736(95)92307-1","article-title":"Neuroleptic sensitivity to risperidone in Lewy body dementia","volume":"346","author":"McKeith","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib91","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(95)91245-2","article-title":"Risperidone for psychotic and behavioural symptoms in Lewy body dementia","volume":"346","author":"Allen","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib92","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/(SICI)1099-1166(199801)13:1<65::AID-GPS731>3.0.CO;2-K","article-title":"Risperidol and withdrawal bruxism in Lewy body dementia","volume":"13","author":"Shiwach","year":"1998","journal-title":"Int. J. Geriatr. Psychiatr."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib93","first-page":"421","article-title":"Combination of risperidone and donepezil in Lewy body dementia","volume":"43","author":"Geizer","year":"1998","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib94","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0278-5846(01)00235-4","article-title":"Improvement of both psychotic symptoms and Parkinsonism in a case of dementia with Lewy bodies by the combination therapy of risperidone and l-DOPA","volume":"26","author":"Kato","year":"2002","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib95","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0278-5846(00)00123-8","article-title":"Risperidone, neuroleptic malignant syndrome and probable dementia with Lewy bodies","volume":"24","author":"Sechi","year":"2000","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib96","doi-asserted-by":"crossref","DOI":"10.1177\/070674370204701018","article-title":"Probable dementia with lewy bodies and risperidone-induced delirium","volume":"47","author":"Morikawa","year":"2002","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib97","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/WAD.0b013e3181e6a4d7","article-title":"Treating neuropsychiatric symptoms in dementia with lewy bodies","volume":"24","author":"Culo","year":"2010","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib98","article-title":"Motor worsening and tardive dyskinesia with aripiprazole in Lewy body dementia","volume":"2009","author":"Boylan","year":"2009","journal-title":"Case Reports"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib99","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3233\/JPD-181448","article-title":"A systematic review and case series of ziprasidone for psychosis in Parkinson's disease","volume":"9","author":"Younce","year":"2019","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib100","first-page":"201","article-title":"Melperone in the treatment of iatrogenic psychosis in Parkinson's disease","volume":"11","author":"Barbato","year":"1996","journal-title":"Funct. Neurol."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib101","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/mds.24942","article-title":"Melperone is ineffective in treating Parkinson's disease psychosis","volume":"27","author":"Friedman","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib102","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/mds.21077","article-title":"Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease","volume":"21","author":"Burn","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib103","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/mds.1204","article-title":"Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial","volume":"16","author":"Reading","year":"2001","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib104","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1185\/030079902125000813","article-title":"Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series","volume":"18","author":"Bullock","year":"2002","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib105","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","article-title":"Rivastigmine for dementia associated with Parkinson's disease","volume":"351","author":"Emre","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib106","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s100720200022","article-title":"Donepezil in the treatment of hallucinations and delusions in Parkinson's disease","volume":"23","author":"Fabbrini","year":"2002","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib107","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00002826-200203000-00009","article-title":"Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease","volume":"25","author":"Bergman","year":"2002","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib108","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1136\/jnnp.2004.050682","article-title":"Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study","volume":"76","author":"Ravina","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib109","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(00)03399-7","article-title":"Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study","volume":"356","author":"McKeith","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib110","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/cns.12484","article-title":"Role of donepezil in the management of neuropsychiatric symptoms in Alzheimer's disease and dementia with lewy bodies","volume":"22","author":"Cummings","year":"2016","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib111","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ana.23557","article-title":"Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial","volume":"72","author":"Mori","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib112","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000351672","article-title":"Long-Term safety and efficacy of donepezil in patients with dementia with lewy bodies: results from a 52-week, open-label, multicenter extension study","volume":"36","author":"Ikeda","year":"2013","journal-title":"Dement. Geriatr. Cognit. Disord."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib113","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13195-014-0083-0","article-title":"Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial","volume":"7","author":"Ikeda","year":"2015","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib114","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/psyg.12089","article-title":"Long-term efficacy of donepezil for relapse of visual hallucinations in patients with dementia with Lewy bodies","volume":"15","author":"Ukai","year":"2015","journal-title":"Psychogeriatrics"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib115","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/jnnp-2014-307659","article-title":"Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis","volume":"86","author":"Wang","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib116","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1176\/appi.ajp.2015.14121582","article-title":"Pharmacological management of lewy body dementia: a systematic review and meta-analysis","volume":"172","author":"Stinton","year":"2015","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.parkreldis.2020.05.026_bib117","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/YCT.0b013e3181c18a3d","article-title":"Marked improvement of psychotic symptoms after electroconvulsive therapy in Parkinson disease","volume":"26","author":"Ueda","year":"2010","journal-title":"J. ECT"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib118","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.pnpbp.2011.05.003","article-title":"Improvements in both psychosis and motor signs in Parkinson's disease, and changes in regional cerebral blood flow after electroconvulsive therapy","volume":"35","author":"Usui","year":"2011","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.parkreldis.2020.05.026_bib119","first-page":"41","article-title":"Parkinson\u2019 s disease psychosis","author":"Jakel","year":"2014","journal-title":"J. Park. Restless Legs Syndr."}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802020301437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802020301437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:18:54Z","timestamp":1761178734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802020301437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":115,"alternative-id":["S1353802020301437"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2020.05.026","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of psychosis in Parkinson's disease and dementia with Lewy Bodies: A review","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2020.05.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}